Touyun Biotech Group Limited

Touyun Biotech Group Limited

HHKEX:1332
0.15
HKD
+0.01
(+10.29%)
715.43MMarket Cap
Touyun Biotech Group Limited
HKEX:1332
(Hong Kong Exchange)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
0.52
0.46
0.49
0.44
0.31
-0.02
0.13
0.14
0.14
0.08
0.1
0.11
0.07
- -
- -
- -
Revenue per Share
0.05
0.02
0.01
0.01
0.28
-0.71
-0.1
-0.1
-0.08
-0.06
-0.03
-0.07
-0.1
-0.03
0.01
- -
Basic EPS, GAAP
0.06
0.02
0.01
0.03
-0.5
0.14
-0.04
-0.06
-0.09
-0.05
-0.11
-0.01
-0.01
-0.02
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.18
0.28
0.29
0.3
0.69
0.48
0.39
0.3
0.22
0.18
0.17
0.09
- -
-0.03
-0.02
-0.02
Book Value per Share
0.18
0.28
0.29
0.3
0.69
0.37
0.3
0.22
0.22
0.17
0.17
0.09
- -
-0.03
-0.02
-0.02
Tangible Book Value per Share
809
851
899
899
914
1,626
2,449
2,449
2,449
2,672
2,795
2,806
2,806
2,806
2,806
2,806
Basic Weighted Avg Shares
419
389
436
397
286
-38
318
349
343
207
284
316
199
8
-5
- -
Sales/Revenue/Turnover
10.5
6.22
3.91
3.05
-35.55
973.12
-42.39
-41.44
-9.64
-24.96
-13.29
-12.58
-43.79
-1,683.03
2,613.8
- -
Operating Margin (%)
6
5
6
5
3
3
9
29
32
28
23
33
37
29
24
- -
Depreciation Expense
38
20
13
10
255
-1,151
-245
-254
-201
-169
-73
-198
-269
-88
27
- -
Net Income, GAAP
10.62
12.44
14.1
13.42
0.41
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
- -
Effective Tax Rate (%)
9.04
5.22
3.08
2.61
89.26
3,058.83
-77.19
-72.79
-58.51
-81.62
-25.73
-62.71
-135.39
-1,149.32
-538.35
- -
Profit Margin (%)
28
115
130
101
576
328
408
118
33
61
-261
-88
-218
-384
-493
-493
Working Capital
- -
- -
- -
- -
- -
- -
299
- -
10
8
8
194
206
33
- -
- -
LT Debt
166
249
262
275
779
1,193
958
727
545
556
487
284
21
-41
27
27
Total Equity
- -
10.24
5.76
3.92
37.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
-35.42
- -
Return on Invested Capital (%)
- -
8.55
3.89
3.47
40.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.43
- -
Return on Capital (%)
- -
9.88
5.28
3.87
48.52
-117.19
-22.89
-30.15
-31.63
-32.8
-15.23
-53.98
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
352
396
413
LT Borrowings
27
4
- -
LT Finance Leases
6
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,806
2,806
2,806
Market Capitalization
522
227
715

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
174
122
98
Cash, Cash Equivalents & STI
70
12
5
Accounts Receivable, Net
22
12
9
Inventories
25
17
18
Total Current Liabilities
558
615
591
Payables & Accruals
- -
- -
- -
ST Debt
352
396
413
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-62.07%
-121.42%
-167.4%
Free Cash Flow
-3.34%
37.35%
-39.23%
Net Income, GAAP
-71%
-9.43%
-130.42%
Sales/Revenue/Turnover
-133.89%
-49.94%
-164.94%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
199
2024
- -
- -
8
2025
- -
- -
-5

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.1
2024
- -
- -
-0.03
2025
- -
- -
0.01

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
Touyun Biotech Group Limited, an investment holding entity, engages in the creation, development, production, and worldwide distribution of sophisticated packaging solutions. The company extends its reach across Hong Kong, mainland China, Europe, and the Americas. Its operational framework encompasses four main divisions: advanced QR Code business offerings, the enduring Packaging Products segment, comprehensive Treasury Investment activities, and its innovative Chlamydomonas Reinhardtii product line. The QR Code Business unit delivers bespoke QR code integration for product packaging, coupled with advertising display and digital solutions. Through its subsidiary, Shanghai TY Technology, it is a key provider of tailored marketing solutions for China's Fast-Moving Consumer Goods (FMCG) sector, leveraging cloud computing and mobile internet technologies for O2O marketing, product traceability, logistics, and extensive big data analytics. The Packaging Products division focuses on the manufacturing and sale of premium cases for watches, jewelry, and eyewear, alongside various bags, pouches, and display units. This segment maintains over thirty years of industry expertise, serving global brands with OEM manufacturing across diverse materials like plastic, wood, metal, paper, and fabric. Meanwhile, the Treasury Investment segment involves actively investing in and trading securities, providing money lending facilities, offering securities brokerage, asset management, and margin financing services. Since 2020, the Chlamydomonas Reinhardtii Product Business segment has been dedicated to the cultivation and sale of micro-algae and related health products, utilizing exclusive non-genetically modified cultivation technology and advanced biological fermentation methods to produce nutrient-rich, plant-based protein products. A recent strategic cooperation agreement, announced in November 2025, outlines sales of at least RMB1 billion in *Chlamydomonas reinhardtii* products from 2026 to 2028. The Group, established in 1989 and headquartered in Wan Chai, Hong Kong, diversified its portfolio from traditional packaging into information technology and health food sectors, having been listed on the Hong Kong Stock Exchange since July 2012.